Tirzepatide represents a groundbreaking therapeutic breakthrough with multifunctional properties. Its unique dual agonism of GLP-1 and GIP receptors offers superior glycemic control, weight management, and cardiovascular benefits. Clinical trials have demonstrated its effectiveness in reducing HbA1c levels, promoting weight loss, and improving metabolic health. Additionally, Tirzepatide shows potential in managing cardiovascular disease and non-alcoholic fatty liver disease. Ongoing research aims to further optimize its clinical application. Overall, Tirzepatide holds immense promise for revolutionizing diabetes and metabolic disorder treatments.

1. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
Comprehensive Metabolic Empowerment:
Unveiling Tirzepatide's Multifaceted Functions
What is Tirzepatide?
Tirzepatide is a novel medication that is FDA approved for the treatment of type 2
diabetes mellitus. Given its potent weight loss properties, buy tirzepatide be used
off-label for obesity treatment.
It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that
are seen with GLP-1 medications such as semaglutide. It is currently implemented as
a second-line diabetes medication, similar to GLP-1 medications, and given as a
once-a-week subcutaneous injectable. The FDA approved peptide Tirzepatide in May
2022.

2. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
How Does Tirzepatide Work?
Tirzepatide is a synthetic peptide; and a dual gastric inhibitory polypeptide (GIP) and
glucagon-like peptide 1 (GLP-1) receptor agonist. It is composed of 39 amino acids
and is an analog of the gastric inhibitory polypeptide. Functionally, it stimulates
insulin release from the pancreas and leads to a reduction of hyperglycemia. In
addition, Tirzepatide also increases the levels of adiponectin. Its dual agonism ability
leads to a more significant reduction of hyperglycemia than GLP-1 agonist agents
alone and lowers the user's appetite.
Tirzepatide Benefits
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and
glucagon-like peptide-1 (GLP-1) receptor agonist, which is FDA-approved for treating
type 2 diabetes mellitus. It is important to note that tirzepatide is not approved for
treating type-1 diabetes mellitus and has not been studied in patients with
pancreatitis. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, leading to
significantly improved glycemic control in type 2 diabetics and significant weight
reduction.
Tirzepatide Results
Patients with obesity and type 2 diabetes (T2D) or with overweight and T2D lost an

3. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
estimated 34. 4 pounds (15. 7%) of body weight with 10 mg and 15 mg of tirzepatide
(Mounjaro; Eli Lilly and Company), according to findings from the SURMOUNT-2
global phase 3 trial. Specifically, tirzepatide at 10 mg reduced body weight by 5% or
more in 79. 2% of patients and reduced average body weight by 12. 8%, while the 15
mg dose reduced weight in 82. 7% of patients and decreased average body weight
by 14. 7%.
Tirzepatide used for Weight Loss
Tirzepatide, is a once-weekly injection to decrease blood sugar. Since 2022 it has
shown remarkable weight-loss effects, and is on fast-track designation for its review
for the treatment of obesity. On average, patients saw an astounding weight-loss of
over 20% of their initial body weight.
Tirzepatide and BPC 157 helps with weight loss by decreasing food intake and
slowing down how fast food travels through your digestive tract. This may help you
feel fuller longer and reduce how much food you eat. Studies show this action may
occur in the brain.
How it works:
●Reduce how much food is eaten.
●Stops the liver from making and releasing too much sugar.

4. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
●Slows down how quickly food leaves the stomach.
●The body releases insulin when blood sugar is high.
●The body removes excess sugar from the blood.
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide acts on BOTH GIP and GLP-1 receptors, while Semaglutide acts only on
GLP-1 receptors. Both drugs are effective weight-loss treatments. Tirzepatide is a
dual-acting GIP (glucose-dependent insulinotropic polypeptide) and GLP-1
(glucagon-like peptide-1) receptor agonist. Both are in the class of drugs known as
incretin mimetics but have some differences.
Lifestyle modifications and calorie restriction will lead to overall better results.
Benefits of weight loss is improved comorbidities of obesity such as diabetes, high
blood pressure, abnormal blood lipids and heart disease which can be seen with as
little as a 5% weight loss.
Tirzepatide Side Effects
The most common side effects of Tirzepatide include nausea, diarrhea, decreased
appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These
are not all the possible side effects of Tirzepatide. Talk to your healthcare provider

5. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
about any side effects you might experience.
References
[1]Lilly :Phase 3 Tirzepatide Results Show Superior A1C And Body Weight
Reductions In Type 2 Diabetes". Business Insider. RTTNews. 19 October 2021.
Archived from the original on 28 October 2021. Retrieved 28 October 2021.
[2]Tirzepatide significantly reduced A1C and body weight in people with type 2
diabetes in two phase 3 trials from Lilly's SURPASS program" (Press release). Eli
Lilly and Company. 17 February 2021. Archived from the original on 28 October 2021.
Retrieved 28 October 2021 – via PR Newswire.
[3]Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in
Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the
original on 29 April 2022. Retrieved 29 April 2022.
[4]Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al.
(September 2020). "Tirzepatide is an imbalanced and biased dual GIP and GLP-1
receptor agonist". JCI Insight. 5 (17). doi:10. 1172/jci. insight. 140532. PMC 7526454.
PMID 32730231.

6. AASraw Biochemical Technology Co., ltd
www.aasraw.com
king@aasraw.com
[5]Frederick MO, Boyse RA, Braden TM, Calvin JR, Campbell BM, Changi SM, et al.
(2021). "Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid
SPPS/LPPS Approach with Continuous Manufacturing". Organic Process Research
& Development. 25 (7):1628–1636.
[6]Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L,
Bergman BK, et al. (August 2021). "Tirzepatide versus Semaglutide Once Weekly in
Patients with Type 2 Diabetes". The New England Journal of Medicine. 385
(6):503–515. doi:10. 1056/NEJMoa2107519.